Premium
Reply to: Graefe‐Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939–946
Author(s) -
Snyder B.,
Polasek T. M.,
Doogue M. P.
Publication year - 2012
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2012.01588.x
Subject(s) - medicine , clinical pharmacology , linagliptin , dipeptidyl peptidase 4 inhibitor , diabetes mellitus , library science , family medicine , type 2 diabetes , pharmacology , endocrinology , computer science